M3DC is engaged through Services Agreements with
  • a large pharmaceutical organization
  • a start-up recently incorporated.
Projects cover a full range of activities including the coordination of an European-funded FP7 project focused on translating basic findings on Nanotechnology into industrial application as well as the clinical development of a novel Disease Modifying AntiNeuropathic Drug (DeMAND). M3DC mission is to establish partnerships to bridge and leverage the capabilities of each individual entity and create an added value to customers through networking.